Based on a long-standing historic track-record, we have state-of-the-art and readily available vaccine platform technologies and development capabilities. In recent years, we further developed these scale-able platform technologies that can be applied to quickly develop vaccines.
In our state-of-the-art facilities, our experienced R&D institute takes your discovery up to Phase I/II clinical trials. Furthermore, we share and transfer our knowledge and technologies to public and private partners worldwide and work on collaborative R&D.
Our aim is worldwide equity in access to affordable vaccines. Achieving our aim requires a wide range of expertises in the field of vaccinology and intense interdisciplinary collaboration.
Intravacc provides the know-how and tools to support the development of innovative ideas from universities and start-ups into concept products that are interesting for pharmaceutical companies who are able to bring vaccines to the market. These crucial development phases from research up to clinical phase I/II studies ask for highly professional expertise and infrastructure.
Through co-development and by transferring vaccine technologies and knowledge, we partner with vaccine manufacturers worldwide to develop or improve their vaccine production processes and analytical assays, thereby enhancing both the quality and the quantity of global vaccine manufacturing.
Our programs and projects are supported by the Netherlands Government, the European Union, the World Health organization (WHO) and the Bill and Melinda Gates Foundation.
With our Polio Expertise Center, we contribute to the eradication of polio worldwide. We use our proven platform technologies to swiftly develop an affordable, high quality polio vaccine in accordance with EMA and WHO requirements.
Polio is a severe disease and once infected, there is no cure. Prevention is the key word, and fortunately there are effective vaccines against polio. To prevent future outbreaks, vaccination will remain necessary, even after eradication. To increase polio vaccine availability and accessibility, on assignment by the World Health Organization, we developed a new inactivated polio vaccine.
Intravacc serves as an expert center to improve your polio vaccine by:
We use a science-based quality by design (QbD) approach following ICH Q8 and ICH Q11 guidelines for low cost-of-goods virus vaccines based on an available scale-down process for inactivated polio vaccines.
By using the weakened and less transmissible Sabin polioviruses in production, the risk of facility related outbreaks can be reduced significantly. Therefore, our technology allows manufacturers to securely produce Sabin-IPV (Inactivated Polio Vaccine), and in this way also actively contribute to the GPEI goals for polio eradication.
In recent clinical studies the new Sabin-IPV was successfully shown to be safe and immunogenic in both adults and infants.
The implementation of post-eradication containment requirements (GAPIII) may influence the activities in future polio virus vaccine research, and in production facilities. Therefore, alternative poliovirus strains and methods are actively being developed that could reduce the risk of facility-associated transmission and may require lower levels of containment. For example, new Oral Polio Vaccine type 2 (nOPV2) strains are being developed as commissioned by the Bill and Melinda Gates Foundation. Currently, based on our established platform technologies, Intravacc is producing the polio virus nOPV2 Master- and Working seed lots in this project under cGMP.
We have longstanding historic track record in transferring knowledge and technology, for example regarding Hib conjugate vaccine, and influenza vaccine (WHO program). Currently, our Sabin-IPV production technology, including the product specific assays, is actively being transferred by hands-on training to local vaccine manufacturers in emerging economies. For example, in this way China, South Korea and India are enabled to safely produce the Sabin-IPV vaccine to vaccinate their local population and for international supply to UNICEF. We are open for new collaborations, and licensure of our unique Sabin-IPV technology.
In parallel, continued process optimization and modernization is ongoing. This will contribute to increase the affordable Sabin-IPV quantities available for the post-eradication era.
The Sabin-IPV vaccine is developed on our proven Vero cell platform technology. These platform technologies can also be applied to quickly develop several other viral vaccines to control emergency outbreaks.
The use of laboratory animals often remains a necessity in biomedical research. Intravacc acknowledges that laboratory animals are sentient beings and as such, have an intrinsic value. Therefore we have an active research program on Replacing, Reducing and Refining animal use; the so-called 3Rs.
It is our ambition to replace the use of animals for routine lot release testing of (classical) vaccines by innovative animal-free techniques and to improve the scientific substantiation of these methods.
To achieve this, Intravacc is developing several methods based on the 3R’s (reduction, refinement & replacement) of which some have already been adopted by the European Pharmacopoeia. In addition, we are a front runner in the development and distribution of a new paradigm in vaccine lot release testing, known as the consistency approach. To promote the implementation of this strategy, we participate in a IMI-funded European consortium on consistency testing.
We have a profound interest to cooperate within both public and industrial partnerships to improve the 3R research, that currently focusses on:
Intravacc acknowledges that laboratory animals are sentient beings and as such, have an intrinsic value. Therefore, we use use high quality and welfare standards for animal experimentation.
We have a long standing track record in the performance of animal experiments. We are specialized in animal model infectiology and vaccinology. Our Animal Research Center has three state-of-the-art animal laboratory facilities for housing different species of experimental animals, e.g. (transgenic) mice, rats, cotton rats, ferrets, guinea pigs, rabbits etc.
All species can be housed in accommodations with different containment restrictions and biosafety levels. The flexibility of the animal facilities (i.e various closed compartments and 65 stainless steel isolators) offers the possibility to create tailor-made conditions for each animal species under the optimal housing restrictions and biosafety level BSL-2/DM-II and BSL-3/DM-III.
We pay specific attention to guarantee the microbiological status of the animals during the study. With ISO 9002 and ISO 14001, GMP and GLP quality requirements we can ensure that animal experiments are carried out at a very high quality level. All animal experiments are performed in accordance with the Dutch Law of animal experiments (Wod) and the European Directive 2010/63/EU. The ethical permissibility of the experiment is assessed before the start of each study and during the experiments the animal welfare is monitored by experts according the Wod.
To ensure state of the art expertise and knowledge, we offer innovative research and have several development programs on vaccine delivery and formulation.
We are continuously working to optimize vaccine design and monitoring strategies. The pillars to support translational vaccinology comprise of:
KNOWLEDGE - What should a certain vaccine ideally look like and why?
TOOLS & ASSAYS - How to optimize and monitor vaccine development?
The way this is accomplished by Intravacc varies from collaboration with research institutes/universities/companies to a customer service, examples include:
The ideal vaccine is highly efficacious, easy to administer, thermostable and capable of providing life-long immunity against a given pathogen. Unfortunately, not all vaccines are ideal.
We aim to optimize the efficacy of existing and future vaccines. In addition, optimization of the administration of vaccines can lead to thermostable, pain free and affordable vaccination. Using its proven track record, Intravacc focuses amongst others on improved and innovative techniques for subcutaneous, intramuscular, dermal and mucosal vaccination. By combining innovation and knowledge into a product-oriented approach Intravacc contributes to improved vaccine delivery worldwide.
The Intravacc Vaccine Delivery Platform focuses with its partners on
Our experienced team is working on the stabilization of vaccines and diagnostics by delivering an appropriate formulation suitable for storage in either a liquid or a dried presentation. We offer various drying methods such as spray-drying, freeze-drying, vacuum-drying or foam-drying depending on your needs. We will execute the work in an ML-II environment and are experienced in formulating and drying of genetically modified microorganisms.
We have a broad arrange of equipment, amongst which are:
Intravacc strives for an efficient optimization of drying processes with a minimal risk for failure to guarantee product excellence. Therefore, we offer the following services:
Intravacc is an experienced, not-for-profit R&D organization. We optimize vaccines, vaccine processes and vaccine technologies. Our aim is to substantially reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide.
Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine R&D.
We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.
Intravacc has all the state-of-the-art facilities available in-house to offer you a wide range of solutions. Our dedicated expert staff work tirelessly at optimizing and innovating not only the vaccines themselves – both viral and bacterial - but also the processes of producing them and technologies for transporting, storing and delivering.
With over 100 years of expertise in vaccines to build on, Intravacc is your partner in innovative translational vaccinology.
Hørsholm, Denmark / Bilthoven, the Netherlands, December 11, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and Intravacc (the Institute for Translational Vaccinology), announc...
Hørsholm, Denmark / Bilthoven, the Netherlands, December 11, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and Intravacc (the Institute for Translational Vaccinology), announce the signing of a collaboration agreement. This agreement strengthens ExpreS2ion’s ability to service customers and partners across the full value chain of vaccine development and expands the commercial opportunities for both organisations. Under the agreement, Intravacc will serve as a preferred GMP (Good Manufacturing Practice) partner for ExpreS2ion. The agreement contains no financial exchange between ExpreS2ion and Intravacc. However, it expands the commercial opportunities in the vaccine field for both organisations.
Memorandum of Understanding
ExpreS2ion, a fully owned subsidiary of ExpreS2ion Biotech Holding AB, and Intravacc, an experienced vaccine R&D institute, have signed a Memorandum of Understanding (MoU). The MoU enables ExpreS2ion to service customers and collaboration partners across the full value chain of development of vaccines, from discovery up till GMP production and clinical trials. Under the agreement, Intravacc will serve as a preferred GMP partner for ExpreS2ion. Serving as a reference for expanded customer outreach, the MoU contains no financial exchange between ExpreS2ion and Intravacc. However, it expands the commercial opportunities in the vaccine field for both organisations.
ExpreS2ion CEO Dr. Steen Klysner comments
“We are very satisfied to expand ExpreS2ion’s capabilities into the manufacturing of vaccines through the establishment of a preferred partnership with Intravacc. This strategic alliance increases ExpreS2ion’s service offerings and continues our repositioning into a one-stop solution provider for vaccine developing SMEs and Pharma companies.”
Intravacc CEO Thijs Veerman Msc comments
“We are proud to serve as a preferred GMP partner for ExpreS2ion and its clientele. Intravacc offers one-stop solutions for GMP production and clinical development and has a strong track record in the technology transfer of vaccine products and knowhow to our partners. Our experience with the development and successful technology transfer of vaccines such as Haemophilus influenzae b and Sabin inactivated Polio vaccine to vaccine manufacturers has paved the way for a fast and product oriented route to market.”
Intravacc, based in Bilthoven, the Netherlands, is an established R&D organisation with more than 100 years’ experience in optimisation of vaccines, vaccine processes and vaccine technologies. Intravacc has state-of-the-art production facilities and its aim is to substantially reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide. More information at www.intravacc.nl.
For further information about Intravacc, please contact:
Thijs Veerman Msc, CEO
Telephone: +31 30 7920445
Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on December 11, 2017.
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion’s unique proprietary platform technology, ExpreS2, is designed to enable accelerated, cost effective development and robust production of complex proteins for new vaccines and diagnostics. Since founded in 2010, more than 250 proteins involved in e.g. malaria and Zika were produced in collaborations with research institutions and companies with a superior efficiency and success rate. ExpreS2ion also develops competitive virus-like-particle based vaccines through its joint venture AdaptVac, which was founded in 2017.